...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Message: Resverlogix in the next 2.5 weeks (plus bonus October event)
Your Vote:
Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
ESC finishes up this Wednesday 8/31. Here's what's on tap for the next two and a half weeks. Of course, we are all expecting a reschedule of the AGM as well. Check out the end of the message for the "bonus" October event.
Rodman and Renshaw on Sept 11-13. Resverlogix will present on Sept 13th, 2:10 PM ET,Resverlogix will be webcasting.
European Association for the Study of Diabetes meeting in Munich Sept 12-16. They will present a poster entitled "Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes patients with atherosclerosis via microbiome activity," which focuses on a new mechanism of how RVX-208 beneficially affects the complement cascade via modulating the hepatic response of trimethylamine oxide (TMAO) to increase complement proteins, as well as RVX-208 suppressing levels of flavin-containing monooxygenase 3 (FMO3), the enzyme that makes TMAO. Full abstract at the end of this previous post.
BioPharm America in Boston Sept 13-15. Resverlogix is listed as a presenting company, but not sure what day they are presenting
Here's the bonus event. Just saw this tonight when I searched for "resverlogix" on Twitter. In a tweet from Life Science Report from 8/25, it linked to a document advertising this:
Resverlogix’s R&D Update with World-Renowned Key Opinion Leaders
Thursday, October 13, 2016 12:00PM – 2:15PM EST
Lunch and Presentations will start at 12:15
The Yale Club of NYC, Roof Top Restaurant
22nd Floor 50 Vanderbilt Avenue at 44th St.
Featuring Presentations from Key Opinion Leaders:
Professor Kausik Ray, MBCHB, MD, MPHIL, FACC, FAHA, FESC, FRCP. Professor of Public Health, Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK. Chairman, Resverlogix BETonMACE Clinical Steering Committee.
Dr. Kamyar Kalantar-Zadeh, MD, MPH, PhD. Professor of Medicine, Epidemiology, Pediatrics and Public Health, University of California, Irvine School of Medicine. Chairman, Resverlogix Renal Clinical Advisory Board.
One American dies every 40 seconds of cardiovascular disease. Diabetic patients have a 2-4 times higher death rate and 68% of people with diabetes over the age of 65 will die from heart disease even if their glucose is well managed. By 2030, the total projected economic burden and direct costs of cardiovascular disease in the U.S. is estimated at $918B annually. We hope you will attend the event to hear from world leading experts on the latest technologies of how this grievous disease burden is being addressed.
Resverlogix Corp. (TSE:RVX) is a leading biotechnology company developing novel drugs for the treatment of high-risk cardiovascular disease, diabetes mellitus and chronic kidney disease via ‘epigenetics’ - modifications of gene expression without altering DNA sequence. Their lead drug candidate apabetalone (RVX-208) is currently in a Phase 3 clinical trial ‘BETonMACE’ for high-risk cardiovascular disease patients with T2 diabetes mellitus to reduce the incidence of Major Adverse Cardiac Events (MACE) in this sick patient group. 15% of patients will also have renal disease. MACE in the BETonMACE study is defined as cardiovascular death, non-fatal myocardial infarction or stroke.
Resverlogix Presenters:
Mr. Donald J. McCaffrey, President and CEO, Co-Founder
Dr. Michael Sweeney, M.D., Senior Vice President of Clinical Development
Dr. Ewelina Kulikowski, Ph.D., Senior Vice President of Research & Development
RSVP
The event is intended for investors, sell-side analysts, investment bankers and business development professionals. Please RSVP in advance if you plan to attend, as space is limited:
Susan A. Noonan
S.A. Noonan Communications, LLC
Phone: +1 (212) 966-3650
Email: susan@sanoonan.com
4 Recommendations
Loading...
Loading...
2
Aug 28, 2016 10:51PM
New Message
Please
login
to post a reply